JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 125 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 6.50 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $106,000 | -82.9% | 34,981 | -61.7% | 0.00% | -100.0% |
| Q1 2022 | $620,000 | -54.0% | 91,271 | -43.5% | 0.00% | -50.0% |
| Q4 2021 | $1,348,000 | +8.5% | 161,426 | -3.4% | 0.00% | 0.0% |
| Q3 2021 | $1,242,000 | +17.2% | 167,192 | +7.2% | 0.00% | 0.0% |
| Q2 2021 | $1,060,000 | -30.4% | 155,952 | +5.2% | 0.00% | 0.0% |
| Q1 2021 | $1,523,000 | +10.6% | 148,295 | -24.6% | 0.00% | 0.0% |
| Q4 2020 | $1,377,000 | -16.7% | 196,658 | -3.0% | 0.00% | -33.3% |
| Q3 2020 | $1,654,000 | -47.3% | 202,736 | -55.4% | 0.00% | -40.0% |
| Q2 2020 | $3,136,000 | +6.1% | 454,474 | -27.0% | 0.01% | 0.0% |
| Q1 2020 | $2,957,000 | +107.1% | 622,495 | +115.8% | 0.01% | +150.0% |
| Q2 2019 | $1,428,000 | -40.5% | 288,422 | -25.5% | 0.00% | -33.3% |
| Q1 2019 | $2,400,000 | +441.8% | 387,175 | +194.6% | 0.00% | +200.0% |
| Q4 2018 | $443,000 | – | 131,443 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 572,829 | $1,340,000 | 100.00% |
| TRV GP III, LLC | 1,148,780 | $2,688,000 | 1.17% |
| COWEN AND COMPANY, LLC | 3,647,430 | $8,535,000 | 0.82% |
| Octagon Capital Advisors LP | 1,400,000 | $3,276,000 | 0.56% |
| Deep Track Capital, LP | 4,259,653 | $9,968,000 | 0.46% |
| PFM Health Sciences, LP | 4,094,488 | $9,581,000 | 0.35% |
| RTW INVESTMENTS, LP | 5,106,341 | $11,949,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $645,000 | 0.24% |
| Monarch Partners Asset Management LLC | 228,370 | $534,000 | 0.16% |
| Orbimed Advisors | 2,928,900 | $6,854,000 | 0.13% |